Origin: Commerce Department opens Section 232 pharma probe

On April 14, 2025, the U.S. Commerce Department announced a national-security investigation into imports of pharmaceuticals and active pharmaceutical ingredients. This move is part of a broader effort to assess the potential risks these imports pose to national security.

The investigation falls under Section 232 of the Trade Expansion Act of 1962, which allows the government to impose tariffs on imports that threaten national security. The Commerce Department's notices were published in the Federal Register, inviting public comments on the matter.

This investigation is seen as a precursor to possible tariffs on pharmaceutical imports, which could significantly impact the industry. However, some reports suggest that the overall threat to the sector may be low due to the exclusion of many drugs from these tariffs.

As of now, there are no specific deadlines or dates mentioned for when any potential tariffs would be implemented following the investigation. The situation remains fluid as public comments are collected and analyzed.

AI-synthesized from multiple reported sources